Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients

Matthias D'Huyvetter; Jens De Vos; Vicky Caveliers; Ilse Vaneycken; Johannes Heemskerk; Francois P. Duhoux; Christel Fontaine; Marian Vanhoeij; Albert D. Windhorst; Frank van der Aa; N. Harry Hendrikse; Jos L.E. Eersels; Hendrik Everaert; Pieterjan Gykiere; Nick Devoogdt; Geert Raes; Tony Lahoutte; Marleen Keyaerts

doi:10.2967/jnumed.120.255679

OtherTheranostics

Open Access

Phase I trial of ¹³¹I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients

Matthias D'Huyvetter, Jens De Vos, Vicky Caveliers, Ilse Vaneycken, Johannes Heemskerk, Francois P. Duhoux, Christel Fontaine, Marian Vanhoeij, Albert D. Windhorst, Frank van der Aa, N. Harry Hendrikse, Jos L.E. Eersels, Hendrik Everaert, Pieterjan Gykiere, Nick Devoogdt, Geert Raes, Tony Lahoutte and Marleen Keyaerts

Journal of Nuclear Medicine December 2020, jnumed.120.255679; DOI: https://doi.org/10.2967/jnumed.120.255679

Matthias D'Huyvetter

1 Precirix NV/SA;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jens De Vos

1 Precirix NV/SA;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Vicky Caveliers

2 In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Belgium;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ilse Vaneycken

3 Nuclear Medicine Department, UZ Brussel;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Johannes Heemskerk

3 Nuclear Medicine Department, UZ Brussel;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Francois P. Duhoux

4 Medical Oncology Department, King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, and Institut de Recherche Experimentale et Clinique, Universite Catholique de Louvain;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christel Fontaine

5 Department of Medical Oncology, UZ Brussel;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Marian Vanhoeij

6 Department of Oncological Surgery, UZ Brussel;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Albert D. Windhorst

7 Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology & Nuclear Medicine

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Frank van der Aa

7 Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology & Nuclear Medicine

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

N. Harry Hendrikse

7 Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology & Nuclear Medicine

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jos L.E. Eersels

2 In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Belgium;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Hendrik Everaert

3 Nuclear Medicine Department, UZ Brussel;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Pieterjan Gykiere

3 Nuclear Medicine Department, UZ Brussel;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Nick Devoogdt

1 Precirix NV/SA;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Geert Raes

1 Precirix NV/SA;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Tony Lahoutte

1 Precirix NV/SA;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Marleen Keyaerts

2 In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Belgium;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 66, Issue 5

May 1, 2025

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Phase I trial of ¹³¹I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients

Journal of Nuclear Medicine Dec 2020, jnumed.120.255679; DOI: 10.2967/jnumed.120.255679

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Phase I trial of ¹³¹I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients

Journal of Nuclear Medicine Dec 2020, jnumed.120.255679; DOI: 10.2967/jnumed.120.255679

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

This Month in JNM

PubMed
Google Scholar

Cited By...

Selection of Single Domain Anti-Transferrin Receptor Antibodies for Blood-Brain Barrier Transcytosis Using a Neurotensin Based Assay and Histological Assessment of Target Engagement in a Mouse Model of Alzheimers Disease-Related Amyloid-Beta Pathology

Google Scholar

Theranostics

Determination of the Intralesional Distribution of Theranostic ¹²⁴I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma
Evidence-Based Clinical Protocols to Monitor Efficacy of [¹⁷⁷Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
¹⁷⁷Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer

Show more Theranostics

Clinical (Radionuclide Therapy)

Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice

Show more Clinical (Radionuclide Therapy)

Keywords

Oncology: Breast
Radioimmunoimaging
radionuclide therapy
Iodine-131
breast cancer
single domain antibody
theranostics

Main menu

User menu

Search

Phase I trial of ¹³¹I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Theranostics

Clinical (Radionuclide Therapy)

Similar Articles

Keywords